The Use of Cytokines and Chemokines in the Cancer Immunotherapy

被引:3
作者
Amedei, Amedeo [1 ,2 ,3 ]
Prisco, Domenico [4 ,5 ]
D'Elios, Mario M. [1 ,2 ,3 ]
机构
[1] Univ Florence, Dept Internal Med, I-50134 Florence, Italy
[2] Univ Careggi, Azienda Osped, Dept Biomed, I-50134 Florence, Italy
[3] Univ Florence, Ctr Oncol Minimally Invas Surg, I-50134 Florence, Italy
[4] Univ Florence, Dept Med & Surg Crit Care, I-50134 Florence, Italy
[5] Univ Careggi, Azienda Osped, Dept Biomed, Patol Med Unit, Florence, Italy
关键词
Cancer; chemokines; clinical trials; cytokines; immunotherapy; inflammation; COLONY-STIMULATING FACTOR; RENAL-CELL CARCINOMA; PHASE-I TRIAL; SEVERE COMBINED IMMUNODEFICIENCY; COOPERATIVE-ONCOLOGY-GROUP; LYMPHOID-TISSUE CHEMOKINE; T-REGULATORY CELLS; HIGH-RISK MELANOMA; QUALITY-OF-LIFE; ANTITUMOR IMMUNITY;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The response of the body to cancer is not a unique mechanism and has many parallels with inflammation and wound healing. Unresolved inflammation generates a microenvironment favorable for cellular transformation and the growth of cancer cells. Chronic tissue damage triggers a repair response that includes the production of growth factors, cytokines and chemokines. Cytokines and chemokines have a crucial role in cancer-related inflammation with consequent, direct and indirect effects on the proliferative and invasive properties of tumor cells. In view of the multifactorial functions of cytokines and chemokines in tumorigenesis, the elucidation of their roles will further advance our understanding of the patho-physiological processes of tumor development and highlights potential innovative anti-cancer strategies. Despite recent advances, main anti-cancer therapies, namely surgery, radiation therapy and chemotherapy, are limited in their ability to treat minimal and metastatic residual disease. Furthermore, the benefit of conventional therapies is often limited by collateral damage to normal tissues. Immunotherapy is a new avenue of cancer treatment being investigated by researchers and clinicians for different cancer types. The aim of this paper is to analyze the recent patents and scientific reviews on the major cytokine/chemokine pathways involved in cancer immunotherapy and discuss their basic biology, clinical relevance and potential directions for future anti-cancer therapeutic applications.
引用
收藏
页码:126 / 142
页数:17
相关论文
共 174 条
[1]   T Cells in Gastric Cancer: Friends or Foes [J].
Amedei, Amedeo ;
Della Bella, Chiara ;
Silvestri, Elena ;
Prisco, Domenico ;
D'Elios, Mario M. .
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2012,
[2]  
Antonia SJ, 2011, US Patent, Patent No. [US20110059137, 20110059137]
[3]   Transgenic expression of human gp100 and RANTES at specific time points for suppression of melanoma [J].
Aravindaram, K. ;
Yu, H-H ;
Lan, C-W ;
Wang, P-H ;
Chen, Y-H ;
Chen, H-M ;
Yagita, H. ;
Yang, N-S .
GENE THERAPY, 2009, 16 (11) :1329-1339
[4]  
Artymiuk P, 2010, US Patent, Patent No. 20100316604
[5]   Interleukin-2: Clinical applications [J].
Atkins, MB .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :12-17
[6]   Chemokines in pathology and medicine [J].
Baggiolini, M .
JOURNAL OF INTERNAL MEDICINE, 2001, 250 (02) :91-104
[7]   Human chemokines: An update [J].
Baggiolini, M ;
Dewald, B ;
Moser, B .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :675-705
[8]   Cancer and the chemokine network [J].
Balkwill, F .
NATURE REVIEWS CANCER, 2004, 4 (07) :540-550
[9]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[10]   Cancer-related inflammation: Common themes and therapeutic opportunities [J].
Balkwill, Frances R. ;
Mantovani, Alberto .
SEMINARS IN CANCER BIOLOGY, 2012, 22 (01) :33-40